Drugs / TSC-204-A0201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05973487 | May 2024 → Dec 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, anogenital human papillomavirus infection, endocervical adenocarcinoma +8 | TScan Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-23 | TScan Therapeutics, Inc. | Regulatory TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors tscan.com ↗
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-23 | TScan Therapeutics, Inc. | TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors tscan.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSC-204-A0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05973487 ↗ |